Quarterly report pursuant to Section 13 or 15(d)

Revenue (Details)

v3.8.0.1
Revenue (Details)
 3 Months Ended
Mar. 31, 2018
USD ($)
item
customer
Mar. 31, 2018
USD ($)
customer
Mar. 31, 2017
USD ($)
Jan. 01, 2018
USD ($)
Dec. 31, 2017
USD ($)
Disaggregation of revenue          
Revenue $ 8,196,000 $ 8,196,000 $ 2,857,000    
Change in Contract with Customer, Liability [Abstract]          
Deferred revenue at beginning of the period   30,090,000      
Cumulative effect of adopting ASC 606         $ 8,645,000
Revenue recognized included in contract liability at beginning of the period   7,870,000      
Change in variable consideration   (3,258,000)      
Change in percentage of completion   2,932,000      
Revenue (8,196,000) (8,196,000) $ (2,857,000)    
Amounts invoiced in the period   4,210,000      
Foreign exchange translation adjustment   1,117,000      
Deferred revenue at end of the period 27,221,000 27,221,000      
Contract assets, liability and receivables          
Remaining performance obligation 47,081,000 47,081,000      
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-04-01          
Contract assets, liability and receivables          
Remaining performance obligation $ 3,162,000 3,162,000      
Remaining performance obligation period 9 months        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01          
Contract assets, liability and receivables          
Remaining performance obligation $ 1,823,000 1,823,000      
Remaining performance obligation period 12 months        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01          
Contract assets, liability and receivables          
Remaining performance obligation $ 42,096,000 $ 42,096,000      
Remaining performance obligation period 12 months        
ASU 2014-09          
Change in Contract with Customer, Liability [Abstract]          
Cumulative effect of adopting ASC 606       $ (8,645,000)  
Under previous revenue guidance          
Change in Contract with Customer, Liability [Abstract]          
Deferred revenue at beginning of the period $ 38,735,000        
Under previous revenue guidance | ASU 2014-09          
Disaggregation of revenue          
Revenue 8,996,000        
Change in Contract with Customer, Liability [Abstract]          
Revenue (8,996,000)        
Development          
Disaggregation of revenue          
Revenue 8,196,000        
Change in Contract with Customer, Liability [Abstract]          
Revenue $ (8,196,000)        
GlaxoSmithKline Intellectual Property Development Ltd          
Contract assets, liability and receivables          
Number of customers | customer 1 1      
Number of geographic locations | item 1